Stockscreener 앱 받기
0.8499
0.01%
-0.000100
시간 외 거래:
.85
0.000100
+0.01%
전일 마감가:
$0.85
열려 있는:
$0.855
하루 거래량:
665.62K
Relative Volume:
6.59
시가총액:
$51.25M
수익:
-
순이익/손실:
$-112.67M
주가수익비율:
-0.4028
EPS:
-2.11
순현금흐름:
$-79.26M
1주 성능:
-2.53%
1개월 성능:
-10.54%
6개월 성능:
-16.68%
1년 성능:
-23.43%
1일 변동 폭
$0.845
$0.8579
1주일 범위
$0.80
$0.92
52주 변동 폭
$0.69
$1.60
크로노스 Stock (KRON) Company Profile
명칭
Kronos Bio Inc
전화
(650) 781-5200
주소
1300 S. EL CAMINO REAL, SAN MATEO
KRON을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| KRON | 0.8499 | 51.25M | 0 | -112.67M | -79.26M | -2.11 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
크로노스 Stock (KRON) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-09-14 | 개시 | Berenberg | Buy |
| 2021-10-20 | 재개 | Cowen | Outperform |
| 2021-06-24 | 개시 | H.C. Wainwright | Buy |
| 2020-11-03 | 개시 | Cowen | Outperform |
| 2020-11-03 | 개시 | Goldman | Buy |
| 2020-11-03 | 개시 | Jefferies | Buy |
| 2020-11-03 | 개시 | Piper Sandler | Overweight |
모두보기
크로노스 주식(KRON)의 최신 뉴스
Kronos Bio Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Kronos Bio Provides Update on Review of Strategic Alternatives - Marketscreener.com
Kronos Bio shares downgraded to hold by TD Cowen - Investing.com India
Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024 - The Manila Times
Kronos Bio Highlights Preclinical Data that Show p300 KAT - GlobeNewswire
Kronos Bio's KB-7898 Shows 50% Reduction in Inflammation Markers in Preclinical Study | KRON Stock News - StockTitan
Kronos Bio stock takes a hit with piper sandler slashing price target - Investing.com
Kronos mulls ‘strategic alternatives’ after axing cancer drug development - Pharmaceutical Technology
Kronos Bio (NASDAQ:KRON) Rating Lowered to "Neutral" at Piper Sandler - MarketBeat
Kronos Bio downgraded by Piper Sandler, TD Cowen (NASDAQ:KRON) - Seeking Alpha
Kronos Bio earnings beat by $0.05, revenue topped estimates - Investing.com UK
Kronos Bio, Inc. (KRON) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Kronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic Alternatives - The Manila Times
Kronos Bio Reports Third Quarter 2024 Financial Results and - GlobeNewswire
Kronos Bio Halts Cancer Drug Trial, Explores Strategic Alternatives Amid Safety Concerns | KRON Stock News - StockTitan
Kronos Bio's Market Cap Drops To US$50m Leaving Insiders With Losses - Simply Wall St
Kronos Bio faces Nasdaq delisting over share price - Investing.com India
Kronos Bio faces Nasdaq delisting over share price By Investing.com - Investing.com UK
Kronos Bio to Present Data at the ASH Annual Meeting from p300 KAT Inhibition Program in Multiple Myeloma - GlobeNewswire
Kronos Bio to Present Breakthrough Multiple Myeloma Treatment Data at ASH 2024 | KRON Stock News - StockTitan
Non-Hodgkin’s Lymphoma Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
Kronos Bio, Inc. (NASDAQ:KRON) Sees Large Decline in Short Interest - Defense World
Layoff Tracker: Compass Pathways to Lay Off 30% of Employees - BioSpace
Non-Hodgkin Lymphoma Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail
Nio Inc ADR (NIO-N) QuotePress Release - The Globe and Mail
Phillips-Van Heusen Corp (PVH-N) QuotePress Release - The Globe and Mail
After Plunging -23.49% in 4 Weeks, Here's Why the Trend Might Reverse for Kronos Bio (KRON) - MSN
Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors - The Manila Times
Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium - GlobeNewswire
Taylor Morrison Home Corp (TMHC-N) QuotePress Release - The Globe and Mail
Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven Tumors - The Manila Times
Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium - GlobeNewswire
Kronos Bio's (KRON) "Overweight" Rating Reaffirmed at Piper Sandler - MarketBeat
Kronos Bio nominates KAT inhibitor as development candidate for Sjögren’s disease - BioWorld Online
Piper Sandler maintains Overweight rating on Kronos Bio shares - Investing.com
Kronos Bio nominates KB-7898 for autoimmune disease treatment - Investing.com
Kronos Bio nominates KB-7898 for autoimmune disease treatment By Investing.com - Investing.com South Africa
Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren's Disease - The Manila Times
Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren’s Disease - GlobeNewswire
Plexium Announces Appointment of Jorge F. DiMartino, M.D., Ph.D. as Chief Medical Officer - PR Newswire
Kronos Bio, Inc. (NASDAQ:KRON) Position Increased by Forefront Analytics LLC - Defense World
Kronos Bio to Present Data at ACR Convergence 2024 to Support p300 KAT Inhibition as an Approach to Anti-Inflammatory Therapy - StockTitan
Kronos Bio to Present Data at ACR Convergence 2024 to - GlobeNewswire
Keros Therapeutics (NASDAQ:KROS) Shares Gap Up to $55.80 - Defense World
Avoro Capital Advisors LLC Reduces Position in Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
Integral Health Asset Management LLC Acquires 45,000 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
How the (KROS) price action is used to our Advantage - Stock Traders Daily
How does Keros Therapeutics Inc (KROS) change from a tortoise to a hare? - SETE News
Kronos Bio highlights istisociclib data at Ovarian Cancer Research Symposium - TipRanks
71,428 Shares in Korro Bio, Inc. (NASDAQ:KRRO) Acquired by Tri Locum Partners LP - MarketBeat
크로노스 (KRON) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.66%
1.11%
자본화:
|
볼륨(24시간):